A new era in the treatment of deadly pancreatic cancer was heralded by scientists this week, thanks to science by the ...

Daraxonrasib belongs to a new class of medicines known as RAS(ON) inhibitors. The drug targets the active form of RAS ...

A new daily pill called daraxonrasib is showing promise against advanced pancreatic cancer in a first-in-human trial of 168 ...

For the roughly 1 to 2 percent of pancreatic-cancer patients whose tumors carry a specific genetic glitch called KRAS G12C, ...

For decades, pancreatic cancer has been one of the most lethal cancers, with few effective treatment options. A new drug, daraxonrasib, targets the KRAS mutation that fuels most pancreatic ...

The landmark success of a drug against an ‘undruggable’ cancer is spurring fresh optimism in the quest to treat seemingly ...

"One of the most amazing things I’ve ever seen," clinician-scientist Samuel Hume wrote alongside a video clip posted on X.

The drug daraxonrasib nearly doubled the overall survival rates of pancreatic cancer patients. Here's how it works and who ...

New research shows a medication called daraxonrasib is helping people with advanced pancreatic cancer live longer.

Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) (Actinium or the Company), a pioneer in the development of targeted ...

A new once-daily pill almost doubled the survival time for patients battling an aggressive and advanced form of pancreatic ...

A phase 3 clinical trial has demonstrated that daraxonrasib significantly improved overall survival and progression-free ...